HomeFileStructural heart disease

Structural heart disease

EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they...

EuroPCR 2022 | LYTEN Trial: V-in-V in Small Annuli

TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges...

EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR

Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular.  Therefore, they...

EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5...

EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement

This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a...

Is High Mean Gradient After Edge-to-Edge Strategy Important?

Edge-to-edge treatment of the mitral valve is currently a valid alternative to surgery in cases of mitral...

Transcatheter Edge-To-Edge Repair Is Favorable for Elderly Patients at High Surgical Risk

Mitral valve prolapse is the most frequent cause of mitral valve regurgitation and is associated to hospitalization...

Is Increased Mitral Valve Gradient After MitraClip a Long-Term Prognostic Factor?

Transcatheter mitral valve repair using the edge-to-edge strategy has become a therapeutic alternative for patients with severe...